In addition to BRCA1/2, growing evidences implicate germline mutations in genes involved in homologous recombination repair pathway such as PALB2 in increased risk of breast and pancreatic cancer [6, 31] and improved sensitivity to therapeutic agents such as platinum-based chemotherapy and poly-ADP-ribose polymerase (PARP) inhibitors [32, 33]. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.